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Summary
Hypothermia is a rare but serious condition that has
been associated with various psychiatric medications.
We present a 76-year-old woman with refractory
mania who developed multiple episodes of severe
hypothermia associated with several psychiatric
medications including olanzapine, quetiapine, valproic
acid and oxcarbazepine. These episodes resolved
following discontinuation of the agents. The patient
had never experienced hypothermia before, despite
having been on these or similar agents for many years.
With traditional treatments for mania not feasible,
other medications were used to treat her including
lithium, clonazepam, gabapentin and the novel protein
kinase c inhibitor tamoxifen. The regimen resulted
in some success and importantly, without triggering
hypothermia. This case alerts clinicians to the rare side
effect of hypothermia in response to various psychiatric
medications, the fact that patients can suddenly
develop this intolerance and suggests possible
medications that may be used safely without triggering
hypothermia.

Background
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Hypothermia, a body temperature less than
35°C/95°F, may be caused by exposure, infection,
adrenal insufficiency, hypothyroidism, drug effects
and lesions of the pituitary or hypothalamus, the
primary brain regions of thermoregulation. Antipsychotics, both typical and atypical, and valproic
acid (VPA) have been associated with hypothermia.
Hypothermia from such agents is rare but is
thought to involve mechanisms of 5-hydroxytryptamine2 (5-HT2) receptors and γ-aminobutyric acid/
gaba-aminobutyric acid (GABA).1–5
We present a 76-year-old woman with severe
mania who had multiple episodes of severe hypothermia in the setting of atypical antipsychotic,
VPA and oxcarbazepine therapy, after years tolerating such medication. The authors would like to
emphasise the importance of this rare potentially
life-threatening adverse effect of neuroleptic-induced hypothermia to all physicians, which occurs
regardless of the duration of drug intake, to help
them identify the condition early and treat it
effectively.

Case presentation
Our patient is a 76-year-old obese (body mass index
36.6 kg/m2) woman treated on a chronic geriatric
psychiatry unit for 3 years for severe refractory
mania. Medical history includes hypothyroidism,
coronary artery disease, atrial fibrillation and hypertension. Her mania is characterised by grandiose
and paranoid delusions, aggressive and hypersexual
behaviours. She had been treated with lithium
300 mg/day, VPA 750 mg/day, olanzapine 5 mg/day,
quetiapine 600 mg/day and lorazepam 1 mg pro
re nata (PRN). Her non-psychiatric medications
included amlodipine 2.5 mg/day, aspirin 325 mg/
day, levothyroxine 88 µg/day, loratadine 10 mg/day,
metoprolol 25 mg/day, furosemide 20 mg/day and
omeprazole 20 mg/day.
Five days prior to her first hypothermia, VPA
was increased to 1000 mg/day for 1 day and then
decreased back to 750 mg/day due to sedation. The
day before the first hypothermia, the patient was
started on trimethoprim/sulfamethoxazole (TMP/
SMX) for a urinary tract infection (UTI). The next
day, the patient appeared confused. She was transferred to the local emergency room (ER), where her
rectal temperature was found to be 33.7°C/92.7°F.
She was admitted to the medical intensive care unit
(MICU) for possible sepsis, started on cefepime
and placed on a Bair Huggers to resolve the hypothermia. Chest X-ray, thyroid-stimulating hormone
(TSH), free thyroxine (free T4), complete blood
count (CBC) and comprehensive metabolic profile
(CMP) were normal; lithium level was 0.4 mmol/L
(0.0–1.5 mmol/L) and total valproate levels were
42.6 µg/mL (normal 50.0–150.0 µg/mL). Blood
cultures were negative and there were no other
signs indicating sepsis. By day 3, she was back at
baseline and the medical team discontinued quetiapine and VPA, uncertain if the hypothermia may
have been precipitated by those medications. She
returned to the psychiatric unit.
Two days following discontinuation of VPA
and quetiapine, her mania worsened leading to an
increase in olanzapine from 5 to 10 mg/day and
finally 20 mg/day. Additionally, quetiapine and
VPA were reintroduced at 300 mg/day and 250 mg/
day, respectively. Improvements were noted for a
period of 1 week, before mania worsened further,
prompting the increase of quetiapine and VPA
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to 600 mg/day and 500 mg/day, respectively. Oxcarbazepine
was initiated as a mood stabiliser and titrated to 600 mg/day.
Following these changes, her temperature trended downwards
from 36.7°C to 35.9°C and then 35.1°C (98°F–96.7°F and then
95.2°F). Psychoactive agents were held as a standing order to
hold psychiatric medications for temperature less than 35°C/95°F
was in place. Olanzapine and VPA, suspected as inciting agents,
were discontinued while other psychiatric medications were
resumed. Urine analysis (UA) conducted at this time revealed a
UTI which was treated with ciprofloxacin. The patient subsequently developed hyponatraemia requiring the discontinuation
of oxcarbazepine.
A month following this borderline event, her mania worsened. Quetiapine was increased to 800 mg/day. Gabapentin
600 mg/day was added to help control mania. Within several
days of these medication changes, hypothermia returned
with a rectal temperature of 32.8°C/91°F. Psychoactive medications were held and she was transferred to the ER, where
rectal temperature was 32.2°C/90°F. ECG, chest X-ray,
cardiac enzymes, CMP, lactic acid, CBC with differential,
TSH, free T4, UA and cultures obtained revealed no abnormalities. Lithium level was 0.7 mmol/L. Patient was warmed
with Bair Huggers, becoming normothermic within 5 hours,
and returned to the psychiatric unit. This was considered her
second true hypothermia.
On return, she was restarted on 300 mg/day quetiapine
every night and titrated over 20 days to 500 mg/day. She then
experienced her third hypothermia with a rectal temperature of
34.4°C/94°F. Due to this, quetiapine suspected as the inciting
agent was subsequently discontinued.
One month following this third hypothermia, her manic
symptoms became extreme including no sleep, aggression and
worsening psychosis. Gabapentin was titrated to 2800 mg/day
with some improvement in sleep but not other manic symptoms. VPA was now reintroduced at 250 mg/day every night
with further titration to 500 mg/day every night. A UA at that
time confirmed a recurrent UTI and TMP/SMX was started.
As a precaution, discontinuing VPA was considered; however,
her manic symptoms were so extreme that VPA was increased
to 1000 mg/day. On the night of the increase in VPA dose, she
became hypothermic with a rectal temperature of 34.7°C/94.5°F.
She was transferred to the ER and treated for hypothermia with
warming blankets. UA demonstrated the UTI had cleared (day 5
of 7-day course of TMP/SMX). VPA level was within therapeutic
range at 60.1 µg/mL (50.0–150.0 µg/mL). She was discharged to
the psychiatry unit. VPA was discontinued as it was thought to
be contributory to the hypothermia.
At this point, the team decided to exclude all agents suspected
to induce hypothermia in the patient, explicitly VPA and all
antipsychotics. Oxcarbazepine was excluded due to hyponatraemia. Gabapentin dose was adjusted to a dose of 3000 mg/
day and lorazepam was replaced with clonazepam with 3 mg/
day.
Two weeks following the fourth hypothermia, she experienced two further hypothermic events within a 48-hour period.
She was on day 2 of a course of TMP/SMX for a known UTI.
Rectal temperature was 33.5°C/92.3°F and she was transferred
to the ER. She was placed on Bair Huggers and discharged
back to the psychiatric unit after a confirmed rectal temperature of 36.8°C/98.3°F. Within 24 hours of being discharged, a
rectal temperature of 35°C/95°F was noted, prompting transfer
back to the ER. A UA conducted at this point was normal. She
was admitted, and after return to normothermia and endocrine
consultation discharged.
2

Investigations
All the above-mentioned UTIs were diagnosed based on positive urinalysis results reflecting elevated leucocyte esterase and
abnormally elevated white cell counts with confirmatory cultures
revealing Morganella morganii and Escherichia coli.
Endocrinology consult was obtained to explore other aetiologies for her hypothermia. An MRI revealed no evidence of
lesions in the pituitary or hypothalamus, regions known to be
involved in thermoregulation. Cortisol levels and cosyntropin
stimulation tests conducted yielded benign results, ruling out
adrenal insufficiency as an aetiology.

Treatment
The treatment team explored options for psychiatric medication given the severity of the mania and the inability to tolerate
antipsychotics, VPA and oxcarbazepine. A clinical trial using
tamoxifen,6 a protein kinase C (PKC) inhibitor successfully used
in refractory mania, was reviewed and a decision made to try it.
Clonazepam, lithium and gabapentin were continued. Lithium
was eventually titrated up to 450 mg/day, likewise gabapentin
was titrated up to 1500 mg/day and clonazepam to 3 mg/day.

Outcome and follow-up
The patient was titrated to tamoxifen 80 mg/day (40 mg two
times per day) without return of any hypothermia, now for
7 months. The tamoxifen appeared to dramatically reduce the
severity of her mania, as the other psychiatric medications had
allowed continued aggression, hypersexual behaviours and
marked psychosis. With the new regimen including tamoxifen,
she generally no longer experiences aggressive or hypersexual
behaviours and is overall pleasant. At times, she has some mood
lability, mild paranoia or verbally inappropriate statement but
there are days where she is noted to have a normal mental state.
This new regimen has not precipitated any further hypothermia,
even with subsequent UTIs. She remains in the care of the
chronic geriatric psychiatric unit.

Discussion
Our patient had multiple severe hypothermias associated with
antipsychotics, VPA and oxcarbazepine.
Case reports exist of hypothermia associated with quetiapine
and olanzapine.7–11 In a report of data from the WHO, atypical
antipsychotics were more likely than other psychiatric medications to induce hypothermia, especially following initiation or
increase in dosing, as was the case in our patient. Olanzapine
and quetiapine were the third and fifth most common psychoactive agents to cause hypothermia, and the third and fourth most
common atypical antipsychotic agents, the most common being
risperidone.1 van Marum et al point out several other medications reported to induce hypothermia include aripiprazole,
ziprasidone, chlorpromazine, haloperidol and so on,1 though it
is important to acknowledge the possibility of reporting bias.
Various mechanisms have been put forward. Antipsychotics
with an affinity for 5-HT2 receptors are thought to have an
association with hypothermia.1 Animal studies using N-phenylpiperazine, a similar structure as aripiprazole, demonstrated
antagonism at 5-HT2 receptors associated with their hypothermic effects.4 Olanzapine is known to potently block 5-HT2A
and 5-HT2C receptors, and has a mild selectivity for 5-HT2A
receptors over dopamine D2 receptors.2 Quetiapine also has
similar antagonistic effects at 5-HT2A receptors.3
Another mechanism is the interaction between antipsychotic
agents with the neuropeptide, neurotensin (NT). Decreased levels
Ajayi OO, Holroyd S. BMJ Case Rep 2017. doi:10.1136/bcr-2017-222462
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of NT may play a role in the psychopathology of schizophrenia.
Typical antipsychotics increase synthesis of NT in the caudate
nucleus and nucleus accumbens of dopamine terminal regions
for the nigroneostriatal and mesolimbic systems. Atypicals such
as olanzapine increase NT in the nucleus accumbens.12 13 NT
plays a role in thermoregulation and in mice, stimulation with
NT receptor agonists results in hypothermia.14
Next, we consider oxcarbazepine and VPA. A review of the
literature revealed no cases of hypothermia associated with
oxcarbazepine monotherapy. A single case report involving
hypothermia in the setting of oxcarbazepine, topiramate and
VPA multitherapy was found. In that case, the hypothermia was
thought secondary to topiramate due to the return to normothermia on topiramate’s discontinuation.15
On the other hand, VPA has numerous reports of hypothermia
secondary to its use both with and without combination with
antipsychotic agents, specifically pipamperone and zotepine.16–19
In the cases of hypothermia with VPA in combination with antipsychotics, hypothermia resolved following discontinuation
of the antipsychotic agents.18 19 In the cases of hypothermia
secondary to VPA without antipsychotics, normothermia was
regained following VPA’s discontinuation.16 17
In this case, the first hypothermia while clouded by a
concurrent UTI, occurred in the setting of olanzapine, quetiapine and VPA combination therapy shortly after a temporary increase in the dose of VPA. We theorise VPA may have
potentiated the ability of the atypical agents to induce hypothermia. There are reports in the literature noting increase
in rare side effects following VPA coadministration with
olanzapine and quetiapine, respectively.20 VPA was noted to
increase plasma concentration of quetiapine by 77% when
coadministered.21 An analysis on the interaction between
VPA and olanzapine/quetiapine noted that VPA decreases
plasma concentration of olanzapine and increases plasma
concentration of quetiapine.20
In the fourth hypothermic event, VPA induced hypothermia
without atypical antipsychotic agents. VPA is theorised to
induce hypothermia via GABA.5 Stimulation of GABA receptors is known to modulate thermoregulation and can induce
hypothermia.22 The current consensus in the literature is that
while VPA does not directly bind GABA receptors, it increases
GABA levels, although the exact mechanism has yet to be
elucidated.5 23 Of note, benzodiazepines interact with GABA
receptors and induce hypothermia at high doses5; however,
the doses in our patient were far too low to have caused
her hypothermia. As for gabapentin, a GABA derivative, a
review of its pharmacology states that it has no ‘appreciable
effect’ on GABA A-receptors nor has the case been proven
with regards to its effect on GABA B-receptor, while its effect
on GABA turnover remains under investigation for clinical
relevance.24
Advanced age is associated with a decline of autonomic
nervous system function and ability to thermoregulate.25–28
We speculate that while our patient’s age may have been a
factor, it was not the determinant factor given the fact that
she has had no further hypothermias in the absence of antipsychotics and VPA.
There are also age-related changes in drug metabolism and
clearance. The current literature has yet to find any appreciable
change in the metabolism or clearance of VPA with increasing
age.29–31 There are some findings that suggest quetiapine and
olanzapine have increased plasma concentration with advancing
age.21 32 Such changes could increase susceptibility to hypothermia following dose increases of these agents.
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We also considered other drug–drug interactions, specifically aspirin and VPA, as aspirin is known to increase
VPA-free serum levels.33 While our patient took 325 mg/day
aspirin throughout her treatment, her free serum VPA levels
assessed on three separate occasions were all in the subtherapeutic range (4, <3 and <3 µg/mL; normal 5–25 µg/mL),
ruling out this as a factor.
Next, medical conditions that could potentiate hypothermia were considered. Our patient has hypothyroidism,
a medical condition known to cause hypothermia. However,
her hypothyroidism was well controlled, normal TSH and
free T4 levels were found repeatedly during and in-between
episodes. Concerning environmental factors, the patient
resided in a temperature-controlled environment and no
other patients on the unit developed hypothermia which
leads us to rule out this factor. Infection, another potential
cause, was present. The first, fourth and fifth hypothermic
events occurred with concurrent UTIs. However, no signs of
systemic bacterial infections were found during these events.
Additionally, the second and third hypothermic events
occurred independent of UTIs or other infection. Lastly,
she has had subsequent UTIs in the absence of the offending
psychiatric medications without further hypothermia. We
propose that UTIs may have played a role in disrupting thermoregulation and predisposing our patient to hypothermia
but were not the determinant cause of her hypothermic
events. As stated previously, primary adrenal insufficiency34
was considered but ruled out in this case.
An MRI performed a month prior to the development of
hypothermia revealed no evidence of lesions in the pituitary
or hypothalamus, regions involved in thermoregulation. It is
recognised that very small vascular lesions could have been
present in either region without visibility on MRI, given
the patient’s vascular risk factors. Based on this, we postulate that such small vascular lesions in either area could
have caused a change in her ability to tolerate the effects
of the psychiatric medications which she had tolerated well
without hypothermia for many years. To our knowledge,
there is no literature reflecting this theory but we think it is
a possibility.
With regards to the efficacy of tamoxifen as a treatment
modality, in the trial reviewed, while pointing out the need
for research replication, results yielded comparable improvements in mania rating to short-term trials of lithium carbonate
and divalproex.6 Subjects who participated in that trial were
patients with a history of difficult to manage bipolar disorder.
The propose mechanism behind its efficacy is tamoxifen’s inhibition of PKC. There is evidence that elevation in PKC activity is

Learning points
►► Re-emphasise hypothermia as a side effect, though rare, of

atypical antipsychotics and valproic acid.

►► Physicians should have an increased index of suspicion for

these neuroleptic agents as hypothermia inducers, even in
cases where patients have used the agents for an extensive
period without such effects prior and especially in the
elderly.
►► Tamoxifen, as well as lithium, gabapentin and clonazepam,
can be an alternative treatment options for refractory mania
in patients where means of other conventional therapy are
non-feasible.
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present in persons with bipolar disorder and may play a role in
some aspects of its manifestation.6
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